Loading
A phase 3 trial of bevacizumab (glioblastoma use) in colorectal cancer, run by National Cancer Institute (NCI), active but no longer recruiting.
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor is a phase 3, randomised interventional study registered as NCT00569127 by National Cancer Institute (NCI), with a registry enrolment figure of 427 participants, started 2007-12-01 and due to reach its primary completion in 2015-01-01. Interventions recorded: Bevacizumab; Laboratory Biomarker Analysis; Octreotide Acetate; Recombinant Interferon Alfa-2b. Conditions listed: Colorectal Neuroendocrine Tumor G1; Gastric Neuroendocrine Tumor G1; Neuroendocrine Neoplasm; Neuroendocrine Tumor; Neuroendocrine Tumor G2. Primary outcome: Central Review-based Progression-Free Survival. Colorectal eligibility wording from the registry: "* Metastatic colorectal carcinoid; patients with metastatic cecal or appendiceal carcinoid tumor are not eligible unless the tumors fit into one of the other high-risk categories (a, b, or c above)". Sites: United States. Results were posted on ClinicalTrials.gov in 2016; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
427 enrolled.
95% CI 12.9 to 19.6; Figures from the ClinicalTrials.gov results section (first posted 2016-04-28), not from a publication · 95% CI 9.6 to 18.6
Source95% CI 33.1 to 42.8; Figures from the ClinicalTrials.gov results section (first posted 2016-04-28), not from a publication · 95% CI 35.8 to 52.6
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Central Review-based Progression-Free Survivalprimary | Octreotide, Bevacizumab | 200 | 16.6 months | 0.93 (0.73 to 1.18) | 0.55 | link |
| Octreotide, Interferon Alpha-2b | 202 | 15.4 months | ||||
| Overall Survival | Octreotide, Bevacizumab | 200 | 35.2 months | - | - | link |
| Octreotide, Interferon Alpha-2b | 202 | 47.3 months |
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.